MindWalk

study demonstrates selective targeting of misfolded tdp-43 with relevance to amyotrophic lateral sclerosis (als), frontotemporal dementia (ftd), and certain forms of alzheimer’s disease victoria, british columbia--(business wire)-- mindwalk holdings corp. (“mindwalk” or the “company”) (nasdaq: hyft) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic tdp-43, a disease-driving protein implicated in amyotrophic lateral sclerosis (als), frontotemporal dementia (ftd), and certain forms of alzheimer’s disease. this achievement, generated through mindwalk’s integrated discovery engines and research ecosystem, demonstrates the company’s ability to discriminate with structural precision between toxic protein conformations and their essential, healthy counterparts, a long-standing challenge in neurodegenerative disease drug development. by defining the disease-driving structural state and anchoring it in bio-native wet-lab validation, mindwalk is resolving both the structural and functional logic of neurodegeneration and converting that understanding into selective, evidence-linked biological assets. “this discovery is a direct validation of our platform strategy,” said dr. jennifer bath, president and chief executive officer of mindwalk. “we are not just discovering antibodies. we are identifying the disease-defining protein state and translating that insight into selective, validated assets with traceable biological evidence behind them. this is what platform-driven execution looks like in debilitating, life-threatening disease.” mindwalk has demonstrated its ability to generate disease-defining biological assets through the creation of monoclonal antibodies and intrabodies that selectively recognize misfolded, pathogenic tdp-43, a protein implicated in nearly all als cases and a significant portion of ftd and alzheimer’s disease cases. the defining feature of this work is selectivity: the ability to distinguish toxic protein conformations from their healthy counterparts, a key determinant of downstream development risk in neurodegenerative drug programs. beyond the specific biology, this work provides external validation of mindwalk’s platform capabilities in a client-driven setting. it demonstrates the company’s ability to systematically identify and characterize disease-driving protein states and translate that understanding into selective, evidence-linked biological assets. strategically, this strengthens mindwalk’s position as a trusted discovery partner for complex neurodegenerative programs and supports expanded opportunities for future collaborations, repeat engagements, and broader application of its platform across similarly challenging disease areas. “every molecule we characterize today strengthens our evidence base for what defines disease and what distinguishes healthy biology,” added dr. bath. “that compounding, evidence-linked learning is what defines a truly bio-native platform.” the full scientific study, “rational generation of monoclonal antibodies and intrabodies selective for pathogenic tdp-43,” is available on biorxiv (doi: 10.1101/2025.06.10.658846). about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by its patented hyft® technology and lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with a fully integrated wet-lab. the platform enables rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics to convert insight into validated candidates with speed and precision. forward looking statement this press release contains forward-looking statements within the meaning of applicable securities laws. forward-looking statements include statements regarding the significance of the discovery and validation described in this release, the company’s discovery capabilities and platform performance, the potential relevance or application of the monoclonal antibodies and intrabodies referenced, the ability to identify and characterize disease-driving protein states, the potential translation of preclinical findings into future research or development programs, and potential future collaboration, partnering, licensing, or commercialization opportunities. forward-looking statements are based on management’s current expectations and assumptions as of the date of this release and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. these risks and uncertainties include, but are not limited to, the preliminary nature of scientific findings reported in a preprint that has not undergone peer review; the possibility that subsequent peer review, additional experiments, or further analysis may produce different or contrary results; scientific and technical challenges inherent in drug discovery and development; uncertainties regarding reproducibility, selectivity, safety, pharmacology, and manufacturability; uncertainties regarding the translation of preclinical findings into clinical outcomes; regulatory requirements and approval processes; the company’s reliance on third-party collaborators, clients, and partners; intellectual property risks and uncertainties; competitive developments; market and macroeconomic conditions; and the company’s ability to execute its strategy, secure resources, and manage growth. except as required by law, mindwalk undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this release. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

validated across influenza a and influenza b, including h3n2 subclade k and zoonotic influenza a subtypes h5, h7, h9 austin, texas--(business wire)-- mindwalk holdings corp. (nasdaq:hyft) (“mindwalk” or the “company”), a bio-native ai therapeutic research and technology company, today announced an advance in its universal influenza program following the identification of a breakthrough functional constraint that persists across influenza viruses despite continual evolution. using its patented hyft® deep data technology, mindwalk identified a functional pattern embedded in influenza biology that remains intact beneath surface-level genetic change. when mindwalk examines what does not change, it is not referring to conserved genetic sequences. it refers to preserved biological constraints; the biophysical requirements influenza must satisfy for infection. influenza remains a major global health threat because influenza viruses continually alter immune-exposed regions of surface proteins, eroding durable protection and forcing reactive vaccine redesign. current u.s. surveillance reflects unusually high influenza activity, described in public reporting as the highest level in approximately 25 years. why influenza keeps beating conventional vaccines most influenza research relies on tracking genetic variation. researchers align sequences, score similarity, and catalog mutations. these methods support surveillance, yet they often miss deeper functional constraints because they operate at the level influenza changes readily. mindwalk’s hyft® pattern technology works without sequence alignment, capturing multi-dimensional functional fingerprints that encode geometry, stability, and biophysical constraints. this reveals functional logic that remains stable even when sequence variation obscures it. this is a layer influenza is constrained from altering without loss of core function required for infection. validation across influenza a subtypes and influenza b lineages using its proprietary hyft pattern framework, mindwalk evaluated the identified functional constraint across influenza a and influenza b datasets spanning multiple hosts. the hyft-defined pattern was confirmed across currently circulating influenza a viruses, including viruses classified within h3n2 subclade k, a genetic subgroup under active global surveillance. the same strict functional pattern was also observed across avian influenza a datasets spanning subtypes h5, h7, and h9, indicating preservation of this constraint across both human and avian influenza backgrounds. mindwalk expanded this analysis beyond influenza a to include influenza b, evaluating representative references from both influenza b lineages, victoria and yamagata, and again observed the same strict hyft-defined functional pattern. in addition, assessment of a representative swine-origin influenza a h1n1 dataset yielded the same result. taken together, mindwalk has now identified this conserved hyft pattern across: influenza a in human datasets, including h3n2 and h3n2 subclade k influenza a in avian datasets, spanning subtypes h5, h7, and h9 influenza a in swine-associated datasets, including h1n1 influenza b across both victoria and yamagata lineages across the influenza datasets evaluated to date, mindwalk has not observed a different way for influenza to meet this functional requirement within the constraints analyzed. these results support the conclusion that the identified pattern reflects an evolutionary constraint shared across influenza a and influenza b, rather than a strain-specific or sequence-dependent feature. “influenza constantly rewrites its genetic script, but it remains tightly constrained by the physics required for infection,” said jennifer bath, ph.d., ceo of mindwalk. “our hyft technology allows us to identify those constraints and design directly against them.” from discovery to biological reasoning and rational vaccine design this advance builds directly on mindwalk’s prior work in rational vaccine design and further supports its bio-native ai and deep data approach. rather than predicting outcomes from incomplete inputs, mindwalk’s lensai™ platform, using the core hyft technology, captures and reasons over biological context, linking sequences, functions, experimental outcomes, and scientific evidence into a continuously learning system. by reasoning directly from biological constraints, mindwalk aims to improve decision quality, reduce downstream failure, and increase the expected value of drug discovery programs. “influenza has been studied for decades, yet researchers kept looking at what changes instead of what does not,” said dirk van hyfte md, phd, chief technology officer of mindwalk. “hyft technology let us step outside sequence thinking and identify a functional constraint influenza must preserve for infection. once you see that layer, the problem stops being about prediction and starts being about design.” influenza program development and out-licensing strategy mindwalk intends to advance its influenza program through a phased, capital-efficient development pathway built around program-level segregation. platform-derived programs are structured as standalone development portfolios, allowing capital, risk, and decision-making to align with each individual asset while preserving the integrity of mindwalk’s core discovery platform. under this approach, the influenza program will progress through additional pre-clinical validation and ind-enabling work within its own dedicated portfolio. this structure is designed to support focused investment, clear value inflection points, and efficient governance as the program advances. following ind-enabling activities and sufficient pre-clinical de-risking, mindwalk plans to out-license the influenza program or enter into strategic development partnerships with global pharmaceutical companies with the scale and infrastructure to advance late-stage development and commercialization. mindwalk also expects to support discussions regarding potential strategic investments and other financing alternatives for the program. about mindwalk mindwalk is a bio-native ai therapeutic research and technology company. through its lensai platform and patented hyft technology, mindwalk generates proprietary biological pattern intelligence designed to support rational vaccine and therapeutic discovery. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “targets,” “seeks,” “potential,” or similar expressions, or by statements that certain actions, events, or results are expected to occur or be achieved. forward-looking statements in this press release include, without limitation, statements regarding the company’s influenza research findings and their interpretation; the identification, characterization, and relevance of hyft patterns; the scope of the company’s universal influenza program, including intended breadth across influenza a and influenza b and across seasonal and zoonotic strains; the initiation, design, timing, and results of planned wet-lab validation activities; the ability to translate the reported findings into immunogens, vaccine candidates, or other development assets; the ability to demonstrate immune accessibility, immunogenicity, safety, breadth, and durability in preclinical studies and, if pursued, clinical settings; the timing and outcome of future development decisions; and the company’s ability to pursue, structure, or complete strategic investments, financing alternatives, collaborations, partnering arrangements, or licensing transactions related to the program. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. forward-looking statements involve known and unknown risks, uncertainties, and other factors that cause actual results, performance, or achievements to differ materially from those expressed or implied. these factors include, among others: the preliminary nature of computational analyses and in silico observations; limitations in available data, sampling, and surveillance inputs; the risk that laboratory studies do not replicate or validate the reported findings; uncertainty regarding whether the identified pattern is immune accessible or yields protective immune responses; risks inherent in vaccine discovery and development, including antigen design, formulation, delivery, manufacturability, stability, and scale-up; the risk that a candidate does not demonstrate acceptable safety, tolerability, immunogenicity, breadth, or durability in preclinical studies or clinical settings; the risk of viral evolution and immune escape that reduces effectiveness; regulatory requirements and uncertainties, including requirements for preclinical packages and clinical trial design; dependence on third-party manufacturers, laboratories, collaborators, suppliers, and other service providers; the need for additional capital and the availability, terms, and timing of strategic investments or other financing alternatives; the ability to enter, maintain, and enforce collaborations, partnering arrangements, or licensing transactions on acceptable terms; intellectual property risks, including the ability to obtain, maintain, defend, and enforce patent and other proprietary rights; competitive developments; and broader economic, market, geopolitical, or regulatory conditions. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. this press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

austin, texas--(business wire)-- mindwalk holdings corp.™ (“mindwalk,” “company,” “we” or “us”) (nasdaq: hyft), bio-native ai company today announces the appointment of industry veteran r. scott areglado as chief financial officer (cfo), effective october 20, 2025. “scott’s extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team,” said dr. jennifer bath, mindwalk ceo. “his proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our bio-native ai platform globally.” mr. areglado brings more than 25 years of financial leadership experience across the healthcare, life sciences, and technology sectors, including extensive expertise in corporate finance, strategic planning, capital markets, and investor relations for publicly traded companies. he has a consistent record of strengthening financial operations, driving revenue growth, and supporting transformative transactions that deliver shareholder value. most recently, mr. areglado served as chief financial officer of brainsway ltd. (nasdaq: bway), a global medical device leader in interventional psychiatry. there, he helped redefine corporate strategy and led eight consecutive quarters of revenue growth while enhancing financial discipline and transparency. he also expanded analyst coverage and investor engagement, strengthening the company’s capital market presence. before joining brainsway, mr. areglado was chief financial officer at icad, inc. (nasdaq: icad), a medical technology company specializing in ai-driven cancer detection and therapy solutions. during his tenure, he successfully led multiple financings totaling more than $50 million, executed strategic partnerships, and supported a series of acquisitions that advanced the company’s product portfolio and market position. earlier in his career, mr. areglado held senior financial roles at amicas, inc. (nasdaq: amcs) and several emerging growth technology companies, where he developed deep expertise in sec reporting, m&a integration, and operational transformation. he began his career in public accounting and holds an mba from babson college and a bba in accounting from the university of massachusetts amherst. mr. areglado added, “mindwalk represents a unique opportunity to apply data-driven financial leadership in support of an organization poised to redefine how ai is applied in life sciences. i am excited to join the team and help advance both our strategic and financial goals as we build long-term value for shareholders.” annual general meeting results and board update mindwalk also announced the results of its 2025 annual general meeting of shareholders, held on october 9, 2025. each of dr. jennifer bath, jon lieber, and dirk witters was elected to the company’s board of directors, and davidson & company llp was re-appointed as auditor for the ensuing fiscal year. in accordance with the company’s majority voting policy, mr. kamil isaev, having received approximately 32% of votes in favor and 68% withheld for his re-election, has tendered his resignation to the board. the board has accepted mr. isaev’s resignation, effective immediately, and wishes to thank him for his valuable contributions to mindwalk’s transformation into a bio-native ai leader. mindwalk will file the complete voting results of the 2025 agm on sedar+ and on form 6-k with the u.s. securities and exchange commission. the board is initiating a search process to fill the resulting vacancy and will provide an update once a successor has been appointed, consistent with the company’s governance framework about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

austin, texas--(business wire)-- mindwalk holdings corp.™ (“mindwalk,” “company,” “we” or “us”) (nasdaq: hyft), a bio-native ai company today announced the appointment of industry veteran thomas w. lynch, ph.d. as chief business officer (cbo), effective october 20, 2025. “tom’s combination of biotech depth and software commercialization expertise directly supports mindwalk’s next path of growth,” said dr. jennifer bath ceo of mindwalk. “as we expand the reach of our hyft-powered deep data platform across pharma and biotech markets worldwide, tom’s leadership in scaling global teams and forging strategic partnerships will be instrumental in creating long-term shareholder value.” dr. lynch is an accomplished industry leader with over two decades of experience focused at the intersection of biotechnology and software innovation. dr. lynch has a strong track record in scaling global commercial organizations, launching high-impact products, and driving market adoption of advanced software and data platforms. his career spans technical sales, client services, and business development, where he has consistently delivered growth by combining deep scientific understanding with disciplined commercial execution. most recently, dr. lynch served as director of technical sales & scientific support at aldevron, where he built and led a new global commercial team, aligning strategies with scientific innovation and client needs. prior to that, as vice president of global sales and client services, dr. lynch spearheaded key initiatives including the introduction of clinical mrna manufacturing services and strategic account expansion that materially advanced aldevron’s market position. these efforts were instrumental in accelerating growth and positioning aldevron for its $9.6b acquisition by danaher life sciences in 2021. earlier in his career, dr. lynch led global commercial operations at dnastar, overseeing sales, distribution, and technical support while successfully launching software products that advanced protein structure prediction and analysis, such as novafold powered by i-tasser. his achievements underscore a proven ability to successfully bring complex scientific software and data platforms to market. dr. lynch also serves on the board of bioforward, wisconsin’s leading biohealth association, where he helped drive industry collaboration, education, and legislative initiatives across wisconsin’s biohealth sector. dr. lynch added: “mindwalk sits at the frontier of ai-native data intelligence in life sciences. i am excited to help accelerate the company’s growth trajectory by translating its powerful technology into solutions that drive measurable value for customers, partners, and investors alike.” mindwalk’s appointment of dr. lynch marks another step in executing its commercial strategy to broaden adoption of its bio-native ai platform, positioning the company to capture a growing share of the multibillion-dollar life sciences data analytics market. about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding mindwalk’s appointment of dr. thomas w. lynch as chief business officer; the expected impact of this appointment on the company’s commercial strategy and growth trajectory; the scalability and adoption of mindwalk’s hyft® technology and lensai™ platform; and the company’s ability to expand its bio-native ai solutions across pharmaceutical and biotechnology markets. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: risks related to the execution of commercial and strategic initiatives; challenges in scaling ai-enabled software adoption in complex enterprise environments; scientific or technical development risks; market acceptance of the company’s technologies; competitive pressures; intellectual property protection; and general economic, regulatory, or geopolitical conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f for the fiscal year ended april 30, 2025, available on the company’s profiles at www.sedarplus.ca and www.sec.gov/edgar. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, mindwalk undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.